Isaac Quiros-Fernandez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Isaac Quiros-Fernandez has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Francisco Siles-Canales
Universidad de Costa Rica, San José, Costa Rica
2 shared publications - Rodrigo Antonio Mora Rodríguez
University of Costa Rica
2 shared publications - Andrea Rojas-Cespedes
Research Center on Tropical Diseases (CIET), Faculty of Microbiology, University of Costa Rica, San José 11501-2060, Costa Rica
1 shared publication - Javier Mora
Centro de Investigación en Cirugía y Cáncer, Universidad de Costa Rica , San José
1 shared publication - Jorge L. Arias-Arias
Centro de Investigación en Enfermedades Tropicales (CIET), Facultad de Microbiología, Universidad de Costa Rica, San José 11501-2060, Costa Rica
1 shared publication - Jose Arturo Molina-Mora
University of Costa Rica
1 shared publication
Latest Publications
- 1 January 2026
- Published by Colegio de Microbiólogos y Químicos Clínicos de Costa Rica in Revista del colegio de microbiólogos y químicos clínicos de Costa Rica
Células como fármacos vivos: innovaciones en terapias celulares adoptivas contra el cáncer
Las terapias celulares adoptivas han revolucionado los tratamientos oncológicos al aprovechar la actividad antitumoral de células inmunes autólogas como fármacos vivos contra tumores. Tres estrategias han demostrado ser efectivas en el tratamiento de diversos cánceres, los linfocitos infiltrantes de tumores, las terapias con linfocitos T que expresan TCRs y células CAR-T antitumorales. La evolución tecnológica ha impulsado mejoras en ingeniería genética y en el diseño de receptores CAR de diferentes generaciones, incrementando la persistencia y eficacia antitumoral. Sin embargo, existen limitaciones, atribuibles a la heterogeneidad antigénica y a la inmunosupresión del microambiente tumoral. En paralelo, la manufactura de estas terapias ha avanzado hacia sistemas cerrados que integran la selección, modificación, expansión y formulación celular, reduciendo los requisitos de infraestructura compleja y facilitando la implementación en sistemas de salud en desarrollo. Las terapias celulares adoptivas han pasado de la investigación experimental a convertirse en terapias aprobadas con alto impacto clínico. Su progresiva implementación en sistemas de salud en desarrollo, como el de Costa Rica, plantea un desafío, pero al mismo tiempo un compromiso ineludible con la población costarricense.
- 1 January 2026
- Published by Colegio de Microbiólogos y Químicos Clínicos de Costa Rica in Revista del colegio de microbiólogos y químicos clínicos de Costa Rica
Células como fármacos vivos: innovaciones en terapias celulares adoptivas contra el cáncer
Las terapias celulares adoptivas han revolucionado los tratamientos oncológicos al aprovechar la actividad antitumoral de células inmunes autólogas como fármacos vivos contra tumores. Tres estrategias han demostrado ser efectivas en el tratamiento de diversos cánceres, los linfocitos infiltrantes de tumores, las terapias con linfocitos T que expresan TCRs y células CAR-T antitumorales. La evolución tecnológica ha impulsado mejoras en ingeniería genética y en el diseño de receptores CAR de diferentes generaciones, incrementando la persistencia y eficacia antitumoral. Sin embargo, existen limitaciones, atribuibles a la heterogeneidad antigénica y a la inmunosupresión del microambiente tumoral. En paralelo, la manufactura de estas terapias ha avanzado hacia sistemas cerrados que integran la selección, modificación, expansión y formulación celular, reduciendo los requisitos de infraestructura compleja y facilitando la implementación en sistemas de salud en desarrollo. Las terapias celulares adoptivas han pasado de la investigación experimental a convertirse en terapias aprobadas con alto impacto clínico. Su progresiva implementación en sistemas de salud en desarrollo, como el de Costa Rica, plantea un desafío, pero al mismo tiempo un compromiso ineludible con la población costarricense.
- Open Access
- 1 January 2022
- Published by Universidad Nacional de Costa Rica in Uniciencia
- Vol. 36 (1) , 1-15
Sphingolipid pathway as a biosensor of cancer chemosensitivity: a proof of principle
Cancer is a complex genetic disease with reduced treatment alternatives due to tumor heterogeneity and drug multiresistance emergence. The sphingolipid (SL) metabolic pathway integrates different responses of cellular stress signals and defines cell survival. Therefore, we suggest studying the perturbations on the sphingolipid pathway (SLP) caused by chemotherapeutic drugs using a systems biology approach to evaluate its functionality as a drug response sensor. We used a sphingomyelin-BODIPY (SM-BOD) sensor to study SL metabolism by flow cytometry and live cell imaging in different cancer models. To decode pathway complexity, we implemented Gussian mixture models, ordinary differential equations models, unsupervised classification algorithms and a fuzzy logic approach to assess its utility as a chemotherapy response sensor. Our results show that chemotherapeutic drugs perturb the SLP in different ways in a cell line-specific manner. In addition, we found that few SM-BOD fluorescence features predict chemosensitivity with high accuracy. Finally, we found that the relative species composition of SL appears to contribute to the resulting cytotoxicity of many treatments. This report offers a conceptual and mathematical framework for developing personalized mathematical models to predict and improve cancer therapy.
- 1 January 2022
- Published by Universidad Nacional de Costa Rica in Uniciencia
- Vol. 36 (1) , 1-15
Open AccessSphingolipid pathway as a biosensor of cancer chemosensitivity: a proof of principle
Cancer is a complex genetic disease with reduced treatment alternatives due to tumor heterogeneity and drug multiresistance emergence. The sphingolipid (SL) metabolic pathway integrates different responses of cellular stress signals and defines cell survival. Therefore, we suggest studying the perturbations on the sphingolipid pathway (SLP) caused by chemotherapeutic drugs using a systems biology approach to evaluate its functionality as a drug response sensor. We used a sphingomyelin-BODIPY (SM-BOD) sensor to study SL metabolism by flow cytometry and live cell imaging in different cancer models. To decode pathway complexity, we implemented Gussian mixture models, ordinary differential equations models, unsupervised classification algorithms and a fuzzy logic approach to assess its utility as a chemotherapy response sensor. Our results show that chemotherapeutic drugs perturb the SLP in different ways in a cell line-specific manner. In addition, we found that few SM-BOD fluorescence features predict chemosensitivity with high accuracy. Finally, we found that the relative species composition of SL appears to contribute to the resulting cytotoxicity of many treatments. This report offers a conceptual and mathematical framework for developing personalized mathematical models to predict and improve cancer therapy.
- Open Access
- 18 September 2021
- Published by MDPI AG in Metabolites
- Vol. 11 (9) , 637
Perturbation-Based Modeling Unveils the Autophagic Modulation of Chemosensitivity and Immunogenicity in Breast Cancer Cells
In the absence of new therapeutic strategies, chemotherapeutic drugs are the most widely used strategy against metastatic breast cancer, in spite of eliciting multiple adverse effects and having low responses with an average 5-year patient survival rate. Among the new therapeutic targets that are currently in clinical trials, here, we addressed the association between the regulation of the metabolic process of autophagy and the exposure of damage-associated molecular patterns associated (DAMPs) to immunogenic cell death (ICD), which has not been previously studied. After validating an mCHR-GFP tandem LC3 sensor capacity to report dynamic changes of the autophagic metabolic flux in response to external stimuli and demonstrating that both basal autophagy levels and response to diverse autophagy regulators fluctuate among different cell lines, we explored the interaction between autophagy modulators and chemotherapeutic agents in regards of cytotoxicity and ICD using three different breast cancer cell lines. Since these interactions are very complex and variable throughout different cell lines, we designed a perturbation-based model in which we propose specific modes of action of chemotherapeutic agents on the autophagic flux and the corresponding strategies of modulation to enhance the response to chemotherapy. Our results point towards a promising therapeutic potential of the metabolic regulation of autophagy to overcome chemotherapy resistance by eliciting ICD.
- 18 September 2021
- Published by MDPI AG in Metabolites
- Vol. 11 (9) , 637
Open AccessPerturbation-Based Modeling Unveils the Autophagic Modulation of Chemosensitivity and Immunogenicity in Breast Cancer Cells
In the absence of new therapeutic strategies, chemotherapeutic drugs are the most widely used strategy against metastatic breast cancer, in spite of eliciting multiple adverse effects and having low responses with an average 5-year patient survival rate. Among the new therapeutic targets that are currently in clinical trials, here, we addressed the association between the regulation of the metabolic process of autophagy and the exposure of damage-associated molecular patterns associated (DAMPs) to immunogenic cell death (ICD), which has not been previously studied. After validating an mCHR-GFP tandem LC3 sensor capacity to report dynamic changes of the autophagic metabolic flux in response to external stimuli and demonstrating that both basal autophagy levels and response to diverse autophagy regulators fluctuate among different cell lines, we explored the interaction between autophagy modulators and chemotherapeutic agents in regards of cytotoxicity and ICD using three different breast cancer cell lines. Since these interactions are very complex and variable throughout different cell lines, we designed a perturbation-based model in which we propose specific modes of action of chemotherapeutic agents on the autophagic flux and the corresponding strategies of modulation to enhance the response to chemotherapy. Our results point towards a promising therapeutic potential of the metabolic regulation of autophagy to overcome chemotherapy resistance by eliciting ICD.